Neuro-Oncology And Brain Tumors Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Neuro-Oncology and Brain Tumors

The nervous system getting affected by cancer is one of the severe conditions. The study of cancers of the nervous system is called Neurooncology. Neuro-Oncology is a branch of medicine concerned with the neoplasms of the brain and spinal cord. In the end, it becomes lethal in most cases. It does study, investigation, identification, and treatment for malignant and benign spinal cord and brain tumors.

Neuro-Oncology deals with various tumors like primary tumors of the Central nervous system (CNS) and metastatic tumors of CNS, and their numerous factors causing them at first place. Some worst cancer forms are gliomas of the pons, gliomas of the brainstem, glioblastoma multiforme, and astrocytoma.

The diagnosis of these brain tumors depends heavily on the diagnostic imaging or imaging of the brain. For diagnosis, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) are mainly used and other tests include Positron Emission Tomography (PET), Myelography and Angiography. The main treatment includes chemotherapy, surgery, radiotherapy, corticosteroids, cancer pain management, and neurosurgical interventions.

Neuro-Oncologists – they are the physician trained to investigate, interpret, diagnose and to treat patients with a brain tumor and tumors of the nervous system.

Sub-tracks:

Neuro-Oncological disorders
Spinal metastasis
Intracranial metastasis
Skull metastasis
Psychosocial Advances in Neuro-Oncology

Market Analysis: The neuro-oncology and brain tumor market is set for significant growth, with a projected Compound Annual Growth Rate (CAGR) between 7.3% and 9.8% from 2025 to 2030. This expansion is driven by the rising incidence of brain tumors and advancements in diagnostics and innovative therapies like targeted treatments and immunotherapy. Specific segments, such as brain tumor therapeutics, are expected to see even higher growth, potentially exceeding an 11% CAGR. This robust outlook highlights the market's strong trajectory in the coming years.

Tracks